Ghisallo Capital Management LLC Makes New $669,000 Investment in MBX Biosciences, Inc. $MBX

Ghisallo Capital Management LLC acquired a new position in MBX Biosciences, Inc. (NASDAQ:MBX) in the third quarter, Holdings Channel.com reports. The firm acquired 38,250 shares of the company’s stock, valued at approximately $669,000.

Several other institutional investors have also recently modified their holdings of MBX. Russell Investments Group Ltd. lifted its position in MBX Biosciences by 4,131.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock worth $26,000 after buying an additional 1,446 shares during the last quarter. BNP Paribas Financial Markets grew its position in MBX Biosciences by 117.9% during the third quarter. BNP Paribas Financial Markets now owns 2,896 shares of the company’s stock valued at $51,000 after acquiring an additional 1,567 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of MBX Biosciences during the third quarter worth approximately $88,000. Virtus Investment Advisers LLC raised its stake in shares of MBX Biosciences by 9.6% during the second quarter. Virtus Investment Advisers LLC now owns 8,772 shares of the company’s stock worth $100,000 after acquiring an additional 766 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of MBX Biosciences by 40.3% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,329 shares of the company’s stock worth $106,000 after acquiring an additional 2,682 shares during the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus upped their price objective on shares of MBX Biosciences from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, December 19th. The Goldman Sachs Group began coverage on shares of MBX Biosciences in a research report on Thursday, December 4th. They issued a “sell” rating and a $18.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of MBX Biosciences in a research note on Thursday, January 22nd. UBS Group restated a “buy” rating on shares of MBX Biosciences in a research report on Tuesday, February 24th. Finally, Wall Street Zen upgraded MBX Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Ten research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $51.56.

MBX Biosciences Stock Performance

NASDAQ:MBX opened at $28.00 on Friday. MBX Biosciences, Inc. has a fifty-two week low of $4.81 and a fifty-two week high of $44.89. The firm has a market cap of $1.26 billion, a PE ratio of -11.62 and a beta of 1.06. The business has a 50 day moving average price of $35.57 and a 200-day moving average price of $26.53.

MBX Biosciences (NASDAQ:MBX) last issued its earnings results on Thursday, March 12th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.15.

MBX Biosciences Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.